Vol 7, No 4 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Squibb Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• identify the molecular pathways involved in malignant transformation and cancer progression,
• recognize and manage superficial bladder cancer based on risk assessment for recurrence and progression,
• know the limitations of bladder-sparing approaches for invasive bladder cancer,
• understand the role of systemic chemotherapy in managing invasive and metastatic bladder cancer, and
• describe pathology features of some unusual thyroid cancers.

This program was planned in accordance with ACCME Essentials.

Release Date: July 1, 2000
Expiration Date: July 1, 2001

Pretest

1. Deletions on which chromosome occur in more than 60% of patients with bladder cancer?

a. 9

b. 11

c. 14

d. 17

2. What 5-year progression-free survival was reported by Loehrer et al for ECOG regarding M-VAC chemotherapy for patients with advanced urothelial cancer?

a. 4%

b. 10%

c. 22%

d. 26%

3. What proportion of patients with medullary carcinoma of the thyroid present sporadically rather than as part of an MEN-2 syndrome?

a. 30%

b. 50%

c. 70%

d. 80%